RNAZ
Transcode Therapeutics, Inc.
Key Financials
Net Income
$-34661076
↓ 106.9%
EPS (Diluted)
$-52.59
↓ 11.6%
Total Liabilities
$10.5M
↑ 12.9%
Operating Income
$-27980071
↓ 78.7%
Shareholders' Equity
$10.3M
↑ 612.0%
Cash & Equivalents
$17.8M
↑ 206.5%
Total Assets
$162.4M
↑ 2126.3%
Operating Cash Flow
$-19516229.00
↓ 46.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| 8-K | 9/28/2026 | View on SEC |
| 3 | 9/21/2026 | View on SEC |
| 4 | 9/11/2026 | View on SEC |
| 8-K | 9/11/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 3 | 8/5/2026 | View on SEC |
| SCHEDULE 13D/A | 8/3/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNAZ |
| Company Name | Transcode Therapeutics, Inc. |
| CIK | 1829635 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-301-6857 |